LAVA Therapeutics Past Earnings Performance
Past criteria checks 0/6
LAVA Therapeutics's earnings have been declining at an average annual rate of -21.2%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 43.2% per year.
Key information
-21.2%
Earnings growth rate
94.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 43.2% |
| Return on equity | -82.0% |
| Net Margin | -620.1% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How LAVA Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -42 | 13 | 34 |
| 30 Sep 23 | 9 | -50 | 14 | 1 |
| 30 Jun 23 | 24 | -41 | 14 | 7 |
| 31 Mar 23 | 20 | -36 | 14 | 2 |
| 31 Dec 22 | 19 | -32 | 14 | 40 |
| 30 Sep 22 | 18 | -25 | 14 | 29 |
| 30 Jun 22 | 5 | -33 | 15 | 16 |
| 31 Mar 22 | 5 | -32 | 15 | 7 |
| 31 Dec 21 | 5 | -42 | 12 | 37 |
| 30 Sep 21 | 6 | -37 | 9 | 1 |
| 30 Jun 21 | 5 | -34 | 6 | 0 |
| 31 Mar 21 | 5 | -31 | 4 | 0 |
| 31 Dec 20 | 4 | -16 | 3 | 0 |
Quality Earnings: LVTX is currently unprofitable.
Growing Profit Margin: LVTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LVTX is unprofitable, and losses have increased over the past 5 years at a rate of 21.2% per year.
Accelerating Growth: Unable to compare LVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: LVTX has a negative Return on Equity (-82.02%), as it is currently unprofitable.